Predictive Oncology raises $343.5 million for digital asset strategy

Predictive Oncology Inc. (NASDAQ: POAI) completed two private placement transactions totaling approximately $343.5 million to support a digital asset treasury strategy focused on ATH, the utility token of the Aethir ecosystem.

The company raised $50.8 million in cash through the sale of approximately 4.4 million shares of common stock at $11.6265 per share. An additional $292.7 million in notional value came from pre-funded warrants issued in exchange for ATH tokens, representing approximately $173.3 million in discounted value of locked and unlocked ATH contributions.

The pre-funded warrants from the cryptocurrency transaction will become exercisable following shareholder approval. Both transactions closed on October 7, 2025.

Predictive Oncology plans to use the ATH contributions for its digital asset treasury strategy and the remaining proceeds to acquire additional ATH tokens in the open market, along with working capital and general corporate purposes.

The company completed a 1-for-15 reverse stock split that became effective September 30, 2025. All share and pricing information reflects post-split figures.

DNA Holdings Venture served as strategic advisor and investor in the cash placement. H.C. Wainwright & Co. acted as exclusive placement agent for both transactions.

Shawn Matthews, CEO of DNA Holdings Venture and former CEO of Cantor Fitzgerald, will join Predictive Oncology's board of directors as previously announced.

Predictive Oncology operates an AI platform called PEDAL for drug discovery and maintains a biobank of over 150,000 tumor samples. The company is based in Pittsburgh.

Information is based on a company press release.

You May Also Be Interested In

• XTEND positions itself for U.S. drone tariff market shift
• CleanCore Solutions to rename itself Zone Frontier Inc. on Aug. 31
• Star Equity to acquire Harte Hanks for $5.00 per share